Emre ERDOĞDU
(Alle Sağlık Kliniği, Perinatoloji Kliniği, İstanbul, Türkiye)
Necdet SUER
(Alle Sağlık Kliniği, Perinatoloji Kliniği, İstanbul, Türkiye)
Yıl: 2020Cilt: 51Sayı: 3ISSN: 1300-7971 / 2148-4864Sayfa Aralığı: 159 - 164İngilizce

23 0
Comparison of the Levonorgestrel-Releasing Intrauterine Systemand Oral Tranexamic Acid in the Treatment of Dysfunctional Uterine Bleeding
Objective: To compare LNG-IUS and oral tranexamic acid in dis-functional uterine bleeding (DUB) therapy in terms of efficacy in reducing blood loss during menstruation, side effects, and comp-liance with therapy.Material and Methods: 60 patients who were diagnosed with DUB and were treated with either oral tranexamic acid 3gr/day or LNG-IUS were included in the study. Bleeding scores (PBAS), duration of bleeding and haemoglobin values before the therapy were recorded. Patients were evaluated again for the same pa-rameters and possible side effects on the 3rd and 6th months of therapy.Results: Decrease in duration of bleeding on the 3rd and 6th months of therapy were statistically significant in both groups (p<0,05). While there was no statistically significant difference on the decrease in the duration of bleeding on the 3rd month of the-rapy (p>0,05), the decrease was more significant in the LNG-IUS group than the tranexamic acid group on the 6th month (p<0,05). In the tranexamic acid group, PBAS dropped by 55 % on the 3rd month, and 62% on the 6th month, but these changes were not significantly different from each other (p>0,05). In the LNG-IUS group, PBAS decreased by 87.5 % on the 3rd month, and 90.5% on the 6th month, and these changes were statistically significant (p<0,05). However, the decrease in the amount of bleeding was significantly more in the LNG-IUS group than the tranexamic acid group (p<0,05). While haemoglobin levels increased 5.6% on the 3rd month and 9.4% on the 6th month in the LNG-IUS group, they increased 3.6% on the 3rd month and 4.5% on the 6th month in the tranexamic acid group. In the LNG-IUS group the most com-mon complaint was mastalgia on the 3rd month of therapy (40%, 10 patients), and oligomenorrhea-amenorrhea on the 6th month (43%, 10 patients). After 6 months, 78% of patients continued the treatment, while 2 patients (6.6%) quit the therapy because of the side effects. In the tranexamic acid group, the compliance rate was 63%, and none of the patients had discontinued the therapy due to side effects.Conclusion: Even though LNG-IUD is more effective than tra-nexamic acid in reducing blood loss in DUB patients, the major change in the menstrual cycle pattern and systemic side effects are the most common reasons for discontinuing therapy. Tranexamic acid reduces blood loss while conserving cycle patterns and ferti-lity, and is better tolerated.
DergiAraştırma MakalesiErişime Açık
  • 1. Fraser IS, Inceboz US. Defining disturbances of the menstrual cycle. In: O’Brien S, Maclean A, Cameron I, eds. Disorders of themenstrual cycle. London: RCOG Press, 2000; 141–52.
  • 2. Wilcox LS, Koonin LM, Pokras R, Strauss LT, Xia Z, Peterson HB. Hysterectomy in the United States, 1988–1990. Obstet Gynecol 1994; 83: 549–55.
  • 3. Kjerulff KH, Langenberg PW, Rhodes JC, Harvey LA, Guzinski GM, Stolley PD. Effectiveness of hysterectomy. Obstet Gynecol 2000; 95: 319–26.
  • 4. Carlson KJ, Miller BA, Fowler FJ Jr. The Maine Women’s Health Study: I. Outcomes of hysterectomy. Obstet Gynecol 1994; 83:556–65.
  • 5. Brooks PG, Clouse J, Morris LS. Hysterectomy vs. resectoscopic endometrial ablation for the control of abnormal uterine bleeding. A cost comparative study. J Reprod Med 1994; 39: 755–60.
  • 6. Sandra E Brooks 1, C Daniel Mullins, Chuanfa Guo, T Timothy Chen, James F Gardner, Claudia R Baquet. Resource utilization for patients undergoing hysterectomy with or without lymph node dissection for` endometrial cancer. Gynecol Oncol 2002; 85: 242–9.
  • 7. Broder MS, Kanouse DE, Mittman BS, Bernstein SJ. The appropriateness of recommendations for hysterectomy. Obstet Gynecol 2000; 95: 199–205.
  • 8. Janssen CA, Scholten PC, Heintz APM. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol 1995; 85: 977–82.
  • 9. Lobo RA, Picker JH, Wild RA, Hirvonen E. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 1994; 84: 987–95.
  • 10. Barrett-Connor E, Slone S, Greendale G, Kritz-Silverstein D, Espeland M, Johnson SR et al. The Postmenopausal Estrogen/Progestin Intervention Study; primary outcome in adherent women. Maturitas 1997; 27: 261–74.
  • 11. Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. Br Med J 1996; 313: 579–82.
  • 12. Callender ST, Warner GT, Cope E. Treatment of menorrhagia with tranexamic acid. A double-blind trial. Br Med J 1970; 4: 214–16.
  • 13. Coulter A, Kelland J, Peto V, Rees MC. Treating menorrhagia in primary care. An overview of drug trials and a survey of prescribing practice. Int J Technol Assess Health Care 1995; 11: 456–71.
  • 14. Milsom I, Anderson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol 1991; 164: 879–83.
  • 15. Kriplani A, Kulshrestha V, Agarwal N, Diwakar S. Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. J Obstet Gynaecol 2006; 26: 673–8.
  • 16. Luukkainen T, Pakarinen P, Toivonen J. Progestin releasing intrauterine systems. Semin Reprod Med 2001; 19: 355–63.
  • 17. Luukkainen T, Allonen H, Haukkamaa M, Holma P, Pyörälä T, Terho J et al. Effective contraception with the levonorgestrel-releasing intrauterine device. 12 month report of a European multicenter study. Contraception 1987; 36: 169–79.
  • 18. Stewart A, Cummins C, Gold L. The effectiveness of the levonorgestrel- releasing intrauterine system in menorrhagia: a systematic review. Br J Obstet Gynaecol 2001; 108: 74–86.
  • 19. Milsom I, Anderson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol 1991; 164: 879–83.
  • 20. Gleeson NC, Buggy F, Sheppard BL, Bonnar J. The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding. Acta Obstet Gynecol Scand 1994; 73: 274–7.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.